银屑病全身治疗网状Meta分析:一项批判性评价
本文总结并评价了两项近期评估中重度银屑病全身治疗的网状Meta分析(NMA)。两项NMA质量高,结果提示靶向IL-12/23和IL-17轴的新型生物制剂似乎比旧生物制剂和口服药物更有效。患者、临床医生和政策制定者可利用NMA的相对疗效评估来指导决策。
要点
- 两项NMA质量高,提供了证据基础和治疗效应的全面总结。
- 靶向IL-12/23和IL-17轴的新型生物制剂似乎比旧生物制剂和口服药物更有效。
- NMA的相对疗效评估可用于指导银屑病皮损清除和生活质量改善的决策。
核心结论
- 两项NMA质量高,结果在估计值和排名上均提示靶向IL-12/23和IL-17轴的新型生物制剂似乎比旧生物制剂和口服药物更有效。
- 患者、临床医生和政策制定者可使用NMA的相对疗效评估来指导关于银屑病皮损清除和生活质量改善的决策。
研究设计与样本
- 两项系统评价检索数据库和灰色文献以识别相关随机临床试验。
- 综述大多纳入涉及中重度银屑病成人的试验,其中一项综述还纳入两项涉及儿童的试验。
主要发现
- 两项NMA质量高,提供了证据基础和治疗效应的全面总结。
- 结果在估计值和排名上均提示靶向IL-12/23和IL-17轴的新型生物制剂似乎比旧生物制剂和口服药物更有效。
关键数值与推荐
- 一项综述以「清除/几乎清除」和因不良事件退出作为研究结局。
- 第二项综述以银屑病面积和严重程度指数(PASI)改善≥90%(PASI 90)和严重不良事件为重点。
- 其他结局包括生活质量、PASI 75、医生整体评估0/1和任何不良事件。
临床怎么用
- 患者、临床医生和政策制定者可使用NMA的相对疗效评估来指导关于银屑病皮损清除和生活质量改善的决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: There are numerous systemic medications in use for psoriasis, with additional investigational agents being studied. However, head-to-head, randomized clinical trials are rare and cannot feasibly compare all treatments. A network meta-analysis (NMA) synthesizes the available evidence to provide estimates for all pairwise comparisons. Here, we summarize and appraise two recent NMAs that assessed systemic therapies for moderate-to-severe psoriasis. SETTING AND DESIGN: Two systematic reviews searched databases and the grey literature to identify relevant randomized clinical trials. STUDY PARTICIPANTS: The reviews mostly included trials that involved adults with moderate-to-severe psoriasis. One of the reviews also included two trials involving children. STUDY EXPOSURE: Interventions common to both reviews include adalimumab, etanercept, infliximab, ustekinumab, ixekizumab, secukinumab and methotrexate. One of the reviews included additional interventions, primarily other biological agents along with new small-molecule treatments and systemic conventional treatments. PRIMARY OUTCOMES: One review focused on 'clear/nearly clear' and withdrawals from adverse events as study outcomes, while the second review focused on improvement of ≥ 90% measured on the Psoriasis Area and Severity Index (PASI 90) and serious adverse events. OUTCOMES: Additional outcomes included quality of life, PASI 75, Physician's Global Assessment of 0/1 and any adverse event. RESULTS: Overall, both NMAs are of high quality and provide a comprehensive summary of the evidence base and treatment effects. Results, in terms of both estimates and rankings, suggest that newer biologics targeting the interleukin (IL)-12/23 and IL-17 axes appear to be more effective than older biologics and oral agents. CONCLUSIONS: Patients, clinicians and policy makers can use the relative efficacy assessments of NMAs to inform decision making regarding the clearance of psoriasis skin lesions at relevant time points and improvement in quality of life.
引用
- Ellis AG, Flohr C, Drucker AM, et al. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535. Br J Dermatol. 2018. PMID: 30347448. doi:10.1111/bjd.17335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。